Anti-Guselkumab antibody

Description:

Anti-Guselkumab is a chimeric rabbit/mouse anti-idiotypic antibody specifically designed to target the human therapeutic antibody Guselkumab. It features rabbit variable domains and mouse constant domains, primarily binding to free Guselkumab in samples.

Target:

Guselkumab is a human IgG1/lambda antibody that recognizes the p19 subunit of interleukin-23 (IL-23) and blocks the IL-23 signaling pathway (1, 2).

The Anti-Guselkumab antibody has been evaluated in ELISA. For other techniques, validation by the user is required. It is recommended to titrate the antibody in the chosen technique, using appropriate negative and positive controls.

For research use only!

Find out more information about the scientific background of the product.

1. Nogueira M, Torres T. Guselkumab for the treatment of psoriasis – evidence to date. Drugs
   Context. 2019; 8.
2. European Medicines Agency (EMA). Tremfya (guselkumab).
   https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya. 2022.
3. Großerichter-Wagener C, Kos D, van Leeuwen A, Dijk L, Jeremiasse J, Loeff FC et al. Biased
   anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics.
   MAbs 2020; 12. PMID:32887534.